PCV42 RECENT TREND IN MANAGEMENT OF HYPERCHOLESTEROLEMIA AND GOAL ATTAINMENT  by Goettsch, WG
A101Abstracts
per year. CHD may adversely impact on the Quality of Life. The
objectives of the study were to describe Health-Related Quality
of Life (HR-QOL) in subjects with CHD and to compare their
health state with the health state of subjects without CHD.
METHODS: We selected subjects with CHD (Cases) from a rep-
resentative sample of the Italian general population aged from
40 to 79 years, enrolled in a population based naturalistic
prospective survey. We matched each of them by age and sex
with subjects without CHD disease (Controls). EuroQoL (EQ-
5D) was used to evaluate HR-QOL. We used Chi Square Test to
evaluate differences in the ﬁve dimensions of the EQ-proﬁle
between the two groups. Paired sample T test was used to eval-
uate differences in EQ-VAS. RESULTS: We analyzed two groups
of 98 subjects per group. The mean age was 64.7 (SD 8.6) years,
(69.4%) were male. More problems were reported in cases than
in controls in the mobility dimension, usual activities, and self
care and anxiety/depression dimensions. These differences
proved statistically signiﬁcant. Whereas in pain/discomfort
domain there was no signiﬁcant difference between the two
groups. Mean values of the visual analogue scale assessing global
health status indicated by case and control were 68.1 and 66.94,
respectively (P = 0.005). CONCLUSION: The study, comparing
subjects of the same age and sex with and without CHD, sug-
gests that the presence of CHD is associated with higher prob-
lems in HR.
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OBJECTIVES: This study aims to describe the health related
quality of life (HRQOL) of the Portuguese population and inves-
tigates sociodemographic differences. METHODS: Subjects ran-
domly selected from the Portuguese active population (n = 2459)
were assessed using the SF-36, a generic measure of HRQOL,
which was converted into the preference-based SF-6D, following
the Brazier algorithm. Although the sample was randomly
selected, it differed slightly from the whole population. In order
to correct this, post-stratiﬁed statically techniques were used to
weight the initial results by gender and age, according to the pop-
ulation values. RESULTS: Mean global utility SF-6D scores were
0.70, and ranged from 0.73 (18–24 years) to 0.63 (55–64 years).
The mean utility scores were 0.17 lower in the lower educational
level than in the higher educational level (p < 0.000). Women,
people living in rural areas and the elderly reported lower levels
of utility scores. Nonparametric tests showed that health utility
values were signiﬁcantly related to employment (p < 0.000): the
unskilled manual workers (0.68) reported lower utility values
than the non-manual workers (0.74). For different diseases mean
utility scores ranged from 0.66 (hepatitis) to 0.56 (stroke). This
study was able to achieve normative data by age and gender for
the SF-6D. Using QALYs as outcome measures, the difference
between unskilled manual workers and non-manual workers
would be equivalent to a difference of 4902€ in annual income.
In this line of thinking, the difference between lower educational
level and higher educational level would be equivalent to a 
difference of 13,889€ in annual income. CONCLUSION: We
conclude that the SF-6D is an efﬁcient tool for measuring the
HRQOL in the community, so that different population groups
can be compared. The preference-based utility measure used
seems to adequately discriminate across different sociodemo-
graphic differences, showing that the HRQOL varies greatly
between sociodemographic groups.
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OBJECTIVES: To evaluate current lipid management practice in
The Netherlands and estimate the impact of new guidelines of
the European Society of Cardiology (ESC) on cholesterol goal
attainment. METHODS: Data were obtained from a sample of
the PHARMO system that includes complete medication, hospi-
tal admission and clinical lab assessment data of 80,000 Dutch
residents. Patients starting lipid lowering drug (LLD) therapy
between 2002–2004 who had a baseline TC measurement in the
six months prior to initiation of therapy and had at least one TC
measurement after the start of therapy were included. Goal
attainment was compared using the ESC 1998 and ESC 2003
guidelines. For both guidelines goal attainment was in general
deﬁned as TC <5mmol/l during LLD treatment. However, in 
the ESC 2003 guidelines goal attainment was deﬁned as TC 
<4.5mmol/l during LLD treatment for patients with cardiovas-
cular disease or diabetes. Doses of statins were expressed in
equipotencies based on TC lowering capabilities. RESULTS: The
study sample comprised of 623 patients (43% females). Most
patients (83%) were initiated on statin monotherapy of at least
an equipotent dose of four (simvastatin 20mg or equipotent
statin). Overall TC goal attainment rate based on 1998 guide-
lines was 59% and based on new ESC guidelines was 49%. Goal
attainment in patients with cardiovascular disease or diabetes
changed from 69% to 49% based on old and new guidelines
respectively. Our results also indicated that persistent statin use
during follow-up increased goal attainment (54% versus 44% in
not persistent patients using new ESC guidelines). CONCLU-
SIONS: Though lipid management in recent years has become
more aggressive, achievement of cholesterol goals based on the
new ESC guidelines is relatively low. Therefore there is a need
for highly effective lipid lowering therapies that are also well tol-
erated in order to achieve sufﬁcient persistence.
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OBJECTIVES: To compare lipid management and reductions in
total cholesterol (TC) levels among patients initiated on lipid
lowering drugs (LLD) in recent years (2002–2004) to those ini-
tiated in earlier years (1991–2001). METHODS: Data were
obtained from a sample of the PHARMO system that includes
complete medication, hospital admission and clinical lab assess-
ment data of 80,000 Dutch residents. Patients starting LLD
therapy and having a baseline TC measurement within six
months prior to therapy initiation as well as at least one mea-
surement after the start of therapy were included in two study
cohorts. One cohort included patients who initiated therapy in
2002–2004 and another that initiated therapy in 1991–2001.
Goal attainment was deﬁned as TC <5mmol/l during LLD treat-
ment according to Dutch guidelines. Statin dosage was expressed
in equipotencies based on TC lowering capabilities. RESULTS:
Patients with cholesterol levels <6mmol/l were more likely to be
treated in the period 2002–2004 than in the period 1991–2001
(27% versus 15% of all patients, respectively). Furthermore,
equipotent dose at the start of statin monotherapy gradually
